July 6, 2021
Austin, Texas – The discovery of the genetic origins of Cannabinoid Hyperemesis Syndrome (CHS) is a major step forward in diagnosing and treating this previously enigmatic and poorly recognized, yet increasingly common condition triggered by high-THC consumption. Symptoms of CHS include intractable nausea, cyclic vomiting, abdominal pain, and hot bathing behavior in episodes that can last for several weeks and represent a grievous health and financial burden to its victims. This study represents the largest patient cohort of CHS patients examined to date, and first to note associated mutations in genes affecting neurotransmitters, the endocannabinoid system (ECS), and the cytochrome P450 complex associated with cannabinoid metabolism.
“These important preliminary findings, contribute to the growing body of knowledge, stimulate additional investigation, help elucidate the pathophysiology of CHS and, ultimately, direct future treatment,” says chief investigator Ethan Russo, MD.
The scientific team was led by Dr. Russo, a world-renowned medical cannabis expert, and Len May, a leader in the field of endocannabinoid system (ECS) genomics. Dr. Russo is a board-certified neurologist, a psychopharmacology researcher, the CEO of CReDO Science, and a prolific author. Mr. May is the co-founder and CEO of Endocanna Health, a sought-after speaker and an author.
“CReDO Science is proud to have partnered with Endocanna Health in publishing this genetic marker discovery that highlights the risks and susceptibility its patients face,” said Dr. Russo. CHS is a relatively new phenomenon, and thus research is lacking in this area. Mr. May shares, “We are honored our discovery advances the science and understanding of this traumatic condition and that it is the first step in developing treatment and providing relief to patients.”
Through Endocanna Health, a CHS genomic test will be available to gastroenterologists and hospital emergency departments by the end of summer 2021. Mr. May explains, “Through genomic testing we can provide peace of mind to those consumers struggling with CHS.” Dr. Russo adds, “Screening patients for this condition will help obviate the need for repetitive hospitalizations, expensive and invasive diagnostics.”
The scientific team, which also includes naturopathic physician and cannabis scientist Chris Spooner, Ryan Leslie and Nishi Whiteley, is “focused on using this data to do a larger clinical study that will create an industry standard for CHS diagnostics,” said Mr. May.
Read the full article at Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation (liebertpub.com).
CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.
Endocanna Health is the industry leader in endocannabinoid system genomic testing and, and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.
